0.768
-0.02 (-2.12%)
| Previous Close | 0.784 |
| Open | 0.772 |
| Volume | 270,420 |
| Avg. Volume (3M) | 424,032 |
| Market Cap | 73,873,472 |
| Price / Earnings (Forward) | 14.27 |
| Price / Sales | 0.500 |
| Price / Book | 0.650 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -25.72% |
| Operating Margin (TTM) | -48.87% |
| Diluted EPS (TTM) | -0.320 |
| Quarterly Revenue Growth (YOY) | -18.40% |
| Total Debt/Equity (MRQ) | 37.12% |
| Current Ratio (MRQ) | 1.66 |
| Operating Cash Flow (TTM) | 6.36 M |
| Levered Free Cash Flow (TTM) | 16.48 M |
| Return on Assets (TTM) | -6.60% |
| Return on Equity (TTM) | -25.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Assertio Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.52% |
| % Held by Institutions | 26.92% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Nov 2025 | Announcement | Assertio Reports Third Quarter 2025 Financial Results |
| 28 Oct 2025 | Announcement | Assertio Announces Leadership Transition |
| 15 Sep 2025 | Announcement | Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV |
| 10 Sep 2025 | Announcement | Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |